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Role of apoptosis-inducing factor, proline dehydrogenase, and
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Department of Biochemistry and Redox Biology Center, University of Nebraska-Lincoln, Lincoln,
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Abstract
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Flavoproteins catalyze a variety of reactions utilizing flavin mononucleotide or flavin adenine
dinucleotide as cofactors. The oxidoreductase properties of flavoenzymes implicate them in redox
homeostasis, oxidative stress, and various cellular processes, including programmed cell death.
Here we explore three critical flavoproteins involved in apoptosis and redox signaling, ie,
apoptosis-inducing factor (AIF), proline dehydrogenase, and NADPH oxidase. These proteins
have diverse biochemical functions and influence apoptotic signaling by unique mechanisms. The
role of AIF in apoptotic signaling is two-fold, with AIF changing intracellular location from the
inner mitochondrial membrane space to the nucleus upon exposure of cells to apoptotic stimuli. In
the mitochondria, AIF enhances mitochondrial bioenergetics and complex I activity/assembly to
help maintain proper cellular redox homeostasis. After translocating to the nucleus, AIF forms a
chromatin degrading complex with other proteins, such as cyclophilin A. AIF translocation from
the mitochondria to the nucleus is triggered by oxidative stress, implicating AIF as a
mitochondrial redox sensor. Proline dehydrogenase is a membrane-associated flavoenzyme in the
mitochondrion that catalyzes the rate-limiting step of proline oxidation. Upregulation of proline
dehydrogenase by the tumor suppressor, p53, leads to enhanced mitochondrial reactive oxygen
species that induce the intrinsic apoptotic pathway. NADPH oxidases are a group of enzymes that
generate reactive oxygen species for oxidative stress and signaling purposes. Upon activation,
NADPH oxidase 2 generates a burst of superoxide in neutrophils that leads to killing of microbes
during phagocytosis. NADPH oxidases also participate in redox signaling that involves hydrogen
peroxide-mediated activation of different pathways regulating cell proliferation and cell death.
Potential therapeutic strategies for each enzyme are also highlighted.
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Introduction
Apoptosis is a controlled, genetically regulated form of cell death. The term apoptosis
(Greek, meaning “falling off”) was coined by Kerr et al in the early 1970s to describe the
mechanism of programmed cell death in healthy human tissues.1 Programmed cell death is
an evolutionarily conserved form of cell suicide and is crucial in plants and animals.2–5 This
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review will focus on the role of flavoproteins in programmed cell death and the interrelated
extrinsic and intrinsic pathways of apoptosis. The mechanisms by which three different
flavoproteins, ie, apoptosis-inducing factor (AIF), proline dehydrogenase, and NADPH
oxidase, contribute to apoptosis and oxidative stress are described, along with therapeutic
strategies for disease intervention.

Extrinsic and intrinsic pathway of apoptosis
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Several comprehensive reviews are available for extrinsic and intrinsic apoptosis.6–8 Here
we will only summarize some of the main features of extrinsic and intrinsic apoptosis. The
extrinsic pathway of apoptosis is mediated at the cell surface by various death receptors such
as Fas, tumor necrosis factor (TNF) receptor 1, death receptor (DR) 3, TNF-related
apoptosis-inducing ligand (TRAIL) receptor 1, TRAIL R2, DR6, p75 nerve growth factor
receptor, and ectodermal dysplasia receptor. Death receptors are activated by specific
ligands, such as the Fas ligand, TNFα, and TRAIL.4,5,9,10 Ligand binding to death receptors
transmits signals that result in recruitment of intracellular death domain-binding partners,
such as Fas-associated death domain and TNF receptor-associated death domain. The Fas
receptor-Fas-associated death domain complex leads to recruitment of specific adaptor
proteins to form a larger complex, termed the death-inducing signaling complex, which
subsequently activates procaspases 8 and 10.7,11 Activated caspases 8 and 10 then activate
downstream caspases 3, 6, and 7.7,10,12 These activated caspases cleave nuclear DNA repair
enzymes and other cellular proteins, such as poly(ADP-ribose) polymer (PARP), cytosolic
phospholipase A2, actin, and lamin, leading to the formation of apoptotic bodies, chromatin
condensation, and DNA fragmentation.5,6,13–15
The intrinsic or mitochondrial apoptotic pathway is primarily initiated in response to cellular
oxidative stress or DNA damage. Ultraviolet radiation or DNA-damaging drugs induce the
intrinsic pathway via p53-mediated transcriptional upregulation of proapoptotic factors of B
cell lymphoma 2 (BCL-2) family members such as BAX, APAF-1, PUMA, and NOXA
genes. These proapoptotic factors inhibit the action of antiapoptotic BCL-2 mediators like
BCL-xL, BCL-w, and myeloid cell factor-1.10,11 Upregulation of the p53 modulator of
apoptosis and other factors, such as dynamin-related protein-1 (a GTPase) and BCL-2
interacting mediator of cell death, promote the oligomerization of BAX (BCL-2-associated
X protein)-BAK (BCL-2 homologous antagonist-killer) which leads to formation of pores in
the outer mitochondrial membrane.16 These outer mitochondrial permeability transition
pores alter the mitochondrial membrane potential and allow release of cytochrome c, AIF,
and endonuclease G (a mitochondrial-specific nuclease) from the mitochondria.
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The cytochrome c released binds to apoptotic protease activating factor-1 in the cytosol to
form a complex called an apoptosome.7 The apoptosome provides a platform for activation
of caspase 9, which subsequently activates downstream caspases 3, 6, and 7.17,18 AIF and
endonuclease G contribute to apoptosis independently of caspase activity by translocating to
the nucleus where they assist in chromatin condensation and DNA fragmentation.19–21 The
extrinsic and intrinsic apoptotic pathways also involve interrelated pathways, which in
certain cell types amplify the effect of apoptosis-inducing signals.21,22 The mitochondrial
apoptotic pathway can be induced by the action of the death-inducing signaling complex
which cleaves cytosolic BCL-2-interacting domain (BID) into truncated BID. Truncated
BID then translocates into the mitochondria to facilitate BAX-BAK dimerization and
mitochondrial permeability transition pore formation.23,24 In addition, calpain, a calciumdependent cysteine protease, has been shown to cleave BID into truncated BID during
induction of the extrinsic apoptotic pathway.25
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The role of AIF in mitochondrial processes and apoptosis has been an interesting area of
research since the discovery of AIF in 1999.3 The initial identification of AIF as a
flavoprotein suggested that it was a novel mitochondrial redox sensor. Subsequent studies
have established that AIF is a proapoptotic bifunctional protein that exhibits distinct
functions according to its compartmentalization in either the mitochondria or the cell
nucleus. However, the physiological function of AIF in the mitochondria and the
mechanisms by which it induces chromatinolysis and cell death are not yet fully known.
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Newly synthesized AIF is targeted to the intermembrane space of the mitochondria where
flavin adenine dinucleotide (FAD) is incorporated into the folded protein.26 A
transmembrane peptide at the N-terminus of AIF anchors it to the inner mitochondrial
membrane.27 The mature form of AIF appears to have a stabilizing influence on complex I
activity of the respiratory chain.28 In response to apoptotic stimuli such as oxidative stress,
AIF is proteolytically cleaved into a soluble form that translocates to the cell nucleus.29
Once in the nucleus, AIF facilitates chromatin condensation and DNA fragmentation,
leading to apoptosis.30 Thus, similar to cytochrome c, AIF is a mitochondrial protein that is
released into the cytosol and translocated to the nucleus, resulting in apoptosis. However,
the mechanisms by which AIF participates in apoptosis are distinct from the intrinsic
pathway involving cytochrome c and are caspase-independent. In the following sections, we
review the structure and biochemical functions of AIF, translocation mechanisms, and the
role of AIF in apoptosis and disease.
AIF structure
Human AIF is encoded as a 67 kDa polypeptide with 613 residues. The precursor protein
contains a mitochondrial localization sequence (residues 1–55), a transmembrane region
(residues 66–84), an FAD binding domain (residues 128–262 and 401–480), an NADH
binding domain (residues 263–400), a nuclear localization sequence (residues 446–452), and
a C-terminal domain (residues 481–613), which has a proline-rich motif (residues 543–554)
and a proline/glutamate/serine/threonine sequence (residues 528–559).28,30 AIF does not
have a canonical DNA binding domain; instead, DNA binding is mediated by positively
charged residues from the FAD and C-terminal domains that form favorable electrostatic
interactions between AIF and DNA.29 The mature form of AIF (residues 55–613, 57 kDa) is
generated by removal of the mitochondrial localization signal peptide and is anchored to the
inner mitochondrial membrane via the transmembrane binding peptide.
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The structure of NADH-treated AIF with the FAD cofactor in the reduced form was
reported, enabling comparison of the oxidized and reduced forms of AIF.28 Oxidized AIF is
a monomer, whereas NADH reduction of the FAD cofactor generates an AIF dimer.28 The
crystal structure indicates that changes on the surface of AIF occur upon reduction,
promoting dimeric interactions. Also, the nuclear localization sequence is less solventaccessible in the dimeric structure, suggesting translocation into the nucleus would be
impeded for the AIF dimer relative to the monomeric form.28,31
Functions of AIF
AIF exhibits distinct functions depending on its subcellular localization in the cell. In the
mitochondria, studies have focused on characterizing the enzymatic activity of AIF with
NADPH and its contribution to mitochondrial function. The FAD cofactor in AIF can be
reduced by both NADH and NADPH, but NADH is the preferred reducing substrate (100fold preference).32,33 However, the rate of reduction of AIF by NADH is relatively slow in
comparison with other NADPH-dependent flavoenzymes.33,34 Upon reduction by NADH, a

Cell Health Cytoskelet. Author manuscript; available in PMC 2012 May 14.

Natarajan and Becker

Page 4

NIH-PA Author Manuscript

charge transfer complex is formed between FADH− and bound NAD+. Interestingly, the
FADH−-NAD+ charge transfer complex is very stable in air, with reduced AIF exhibiting a
high affinity for NAD+ (Kd of 5–80 nM).33
AIF has been reported to generate superoxide, but the sluggish activity of reduced AIF with
oxygen argues against AIF having meaningful NADH oxidase activity in vivo.32 Recently,
Miseviciene et al tested the reactivity of mouse AIF with different quinones. AIF exhibited
NADH:quinone oxidoreductase activity, but the rate was much lower (104-fold lower) than
that of other quinone reductases, such as NADPH:quinone oxidoreductase.34 Thus, it was
concluded that AIF does not contribute significantly to reduction of quinone drugs in vivo.
Whether the quinone reductase activity of AIF is physiologically important is not clear. It
was suggested that reactivity of AIF with quinones may interfere with NADH reduction of
AIF and the overall redox homeostasis of mitochondrial AIF.34 Clearly, further studies are
needed to identify other potential oxidizing substrates of AIF.
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Despite not having a clear enzymatic role, it is well established that AIF has a significant
influence on mitochondrial function. Studies have shown that AIF deficiency or low
expression of AIF generally decreases oxidative phosphorylation, even though AIF is not
part of complex I in the electron transport chain.35–38 Changes in AIF expression are
strongly correlated with mitochondrial complex I activity, with loss of mitochondrial AIF
generally leading to increased oxidative stress. Inactivation of AIF in the early mouse
embryo impaired respiratory complex I activity and led to increased cell death.39 Thus,
reduction of AIF function leads to lower mitochondrial respiration and altered energy
metabolism.
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Other results supporting a role for AIF in respiratory activity are from studies of AIFdeficient mice harboring a proviral insertion in the AIF gene, known as the Harlequin
mutation.35 Knockout of AIF in mice is embryonically lethal, so Harlequin (Hq) mice are a
widely used AIF-deficient animal model used to study the deficiency of AIF. In Hq mice,
AIF expression is decreased by 80%–90% relative to wild-type mice, making these mice a
useful model for evaluating the physiological role of AIF in complex I function and
oxidative phosphorylation.35,40 The Hq mice are characterized by a 50% drop in complex I
activity, and show evidence of elevated oxidative stress in the heart, brain, and cerebellum,
with increased lipid peroxidation and mitochondrial DNA damage.35,41 In addition, T cells
isolated from Hq mice are more sensitive to Fas ligand-induced cell death than are wild-type
controls.26,41 Hq mice are also resistant to cell death induced by the PARP activator, which
suggests a role for AIF in PARP activation.35 The observation of increased oxidative stress
in Hq mice led to the proposal that AIF functions as an antioxidant enzyme.42,43 However,
in vitro knockdown studies of AIF did not provide solid evidence for AIF having an
antioxidant role.42 AIF-deficient cells were shown to have a dramatic loss of cell
tumorigenicity in mice due to the loss of complex I activity.42,44 More studies are needed to
understand the molecular details of how AIF influences redox homeostasis and protects
complex I activity and mitochondrial bioenergetics.36,45
In the nucleus, the function of AIF is to promote chromatin condensation and DNA
fragmentation. Thus, attention has focused on understanding the DNA binding properties of
AIF and the mechanisms by which it initiates DNA fragmentation and apoptotic events. As
mentioned above, AIF does not have a canonical DNA binding domain, but x-ray crystal
structures of AIF have revealed positively charged surface areas that are complementary to
the negatively charged phosphate backbone of the DNA.29,46 AIF has been shown to bind
double-stranded and single-stranded DNA and RNA.47 AIF-DNA binding leads to
condensation of the DNA, possibly through cooperative interactions of AIF proteins on the
DNA.47 Thus, AIF-DNA interactions alone are sufficient to generate higher-ordered DNA
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structures, which presumably would facilitate chromatin condensation, a fundamental
feature of apoptosis.47 The mechanisms by which AIF contribute to DNA fragmentation in
the nucleus are less certain. It appears that AIF lacks nuclease activity, so AIF most likely
helps to recruit other proteins to the DNA for chromatin degradation. One such protein is
cyclophilin A, which normally catalyzes the cis-trans isomerization of peptidyl-prolyl bonds
in target proteins, but has also been reported to have calcium-dependent nuclease activity.48
Although AIF shows no independent DNA nicking activity, the combination of AIF and
cyclophilin A caused degradation of plasmid DNA in vitro, suggesting that AIF and
cyclophilin A may work synergistically in the nucleus to degrade chromatin.49 A cyclophilin
A interaction domain of about 30 amino acids (367–399) in AIF was identified, supporting
the formation of an AIF-cyclophilin A complex.49 More recently, it was found that AIF
interacts with histone H2AX, a member of the histone H2A family and part of the histone
nucleosome core.50 Interactions between AIF and H2AX were suggested to involve the
proline-rich motif of AIF.50 It was proposed that AIF, cyclophilin A, and H2AX form a
complex in the nucleus that promotes chromatinolysis and programmed cell death. H2AX
most likely provides AIF/cyclophilin A with access to the DNA to facilitate degradation of
chromatin (see Figure 1).
AIF translocation and redox regulation
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The function of AIF is determined by its localization in the cell. Thus, understanding the
regulation of AIF localization is critical to understanding the mechanisms by which AIF
induces apoptosis. Figure 1 summarizes the overall mechanism of AIF translocation to the
nucleus and activation of apoptosis. The mitochondrial location of AIF and its relationship
with complex I activity indicates a possible redox mechanism for AIF regulation. Evidence
for redox regulation of AIF has been reported from analysis of the AIF oligomeric structure.
In the presence of NADH, AIF is primarily a dimer whereas in the absence of NADH, AIF
is mainly a monomer.28 Thus, AIF exists in dimer-monomer equilibrium, with NADH
reduction of the bound FAD favoring the dimeric form and oxidation driving formation of
the AIF monomer.28 AIF localization in the inner mitochondrial membrane is ideal for
responding to intracellular redox changes, such as the NADH/NAD+ ratio. Decreased
NADH levels associated with oxidative stress and apoptotic insults would be predicted to
shift AIF toward the monomeric form.30 The significance of the redox regulation of AIF
dimer-monomer equilibrium is that the AIF monomer appears to have increased
susceptibility to proteolysis at the N-terminal membrane binding domain. Apoptotic AIF is
generated by proteolytic processing of mature AIF upon apoptotic insult, oxidative stress, or
mitochondrial membrane rupture. In particular, the Ca2+-dependent cysteine protease, μcalpain (also known as calpain-I), is thought to have a major role in protease-dependent
release of AIF from the mitochondrial inner membrane.3,8,45,51 Treatment of isolated
mitochondria with a calpain inhibitor abolished AIF release.26 Thus, oxidative conditions
which favor the monomeric form of AIF also lead to increased proteolytic susceptibility and
processing.
Newly cleaved AIF breaks out of the mitochondria by traversing BAX/BAK pores in the
outer mitochondrial membrane.27 AIF can also escape from the inner mitochondria
membrane space via the mitochondrial permeability transition pores. This was shown by
inhibition of AIF release by cyclosporin A, a permeability transition pore inhibitor.32 AIF
release is also diminished by increased expression of BCL-2, an antiapoptotic protein which
prevents formation of the mitochondrial membrane transition pore. Although liberation of
AIF from the mitochondria is caspase-independent, it has been suggested that caspases
increase mitochondrial permeabilization and thereby facilitate calpain-dependent release of
AIF from the mitochondria.50,52 A consequence of AIF proteolysis and release from the
inner membrane space is decreased complex I activity and oxidative phosphorylation. These
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effects eventually lead to increased generation of reactive oxygen species, mitochondrial
swelling, and rupture of the outer membrane, resulting in accelerated release of AIF from
the mitochondria.30
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Upon leaving the mitochondria, AIF translocates to the cell nucleus where it assumes its
apoptotic function. AIF has also been proposed to interact with a number of functionally
diverse proteins in the cytosol that either inhibit or enhance its translocation to the cell
nucleus. For example, heat shock protein (HSP) 70 has been shown to intercept AIF en route
to the nucleus, forming an AIF-HSP70 complex and thereby retaining AIF in the cytosol and
inhibiting apoptosis.53 Interactions between AIF and cyclophilin A seem to enhance
translocation of AIF into the nucleus because AIF fails to induce apoptosis in cyclophilin A
knockout cells.49 AIF has also been suggested to interact with phospholipid scramblase (an
ATP-dependent phospholipid translocating enzyme), eukaryotic translation initiation factor
3, thioredoxin 2, T-cell ubiquitin ligand, and scythe.26 All of these proteins have been
proposed to promote AIF translocation into the nucleus.30 Scythe (HLA-B-associated
transcript 3) is a regulator of apoptosis in mammalian development. Inactivation of scythe in
mice leads to embryonic or perinatal lethality due to development defects consistent with it
having a role in facilitating the apoptotic function of AIF.30 Scythe-deficient cells are less
sensitive to endoplasmic reticulum stress-induced apoptosis.54 Desmots et al demonstrated
that scythe interacts with AIF in the cytosol in response to stress on the endoplasmic
reticulum.54 It was proposed that AIF-scythe interaction functions as a regulatory complex
to enhance apoptogenic activity of AIF.54
Another mechanism of AIF translocation relates to parthanatos cell death involving
interactions with PARP.55 Activation of PARP-1, a nuclear DNA repair enzyme, leads to
increased levels of poly(ADP-ribose) (PAR), which subsequently increase AIF translocation
to the nucleus.27,56 PAR have been shown to bind to AIF in the mitochondria, forming an
AIF-PAR complex that escapes from the mitochondria and translocates to the nucleus,
resulting in chromatin condensation and DNA cleavage during parthanatos.55 Recently,
Wang et al identified a PAR binding site in AIF which is distinct from its DNA binding
site.57 The functional importance of the PAR binding site was demonstrated by
characterization of the triple PAR binding mutant (Pbm)-AIF (R588A, K589A, K592A).
Pbm-AIF defective in PAR binding was not translocated to the nucleus by activation of
PARP-1 in response to cellular DNA damage.57 The small pool of AIF present in the outer
mitochondrial membrane of the rat brain has also been proposed to translocate rapidly to the
nucleus in response to PAR-induced parthanatos.58
Implications in disease
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A deletion mutation in the AIF gene has been associated with the severe X-linked
mitochondrial encephalomyopathy disorder characterized by axonal sensory and motor
peripheral neuropathy, and severe muscular atrophy. A deletion of base pairs 601–603 in
exon 5 of the human AIF gene results in the loss of the Arg201 codon.31 The AIF Arg201Δ
mutant has been found in two patients.31 In the structure of human AIF, Arg201 (Arg 200 in
the mouse) was shown to be part of the 191–203 β-hairpin which helps to form the FAD
binding pocket and gives conformational stability to the flavoprotein. Arg201 was also
observed to form a salt bridge with Glu531. The importance of Arg201 in FAD binding was
further demonstrated by characterization of the AIF Arg201Δ mutant protein, which was
found to contain less FAD relative to wild-type AIF.31 Thus, the deletion of the Arg201
codon has a clear functional consequence that leads to a less stable AIF protein.
Fibroblasts isolated from patients with AIF Arg201Δ showed partially reduced
mitochondrial complex I, III, and IV activity and decreased oxidative phosphorylation.31
These fibroblasts upon exposure to staurosporine, a protein kinase C inhibitor that induces
Cell Health Cytoskelet. Author manuscript; available in PMC 2012 May 14.
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cell death through the mitochondria-mediated pathway, showed significantly higher levels of
morphologically altered nuclei than control fibroblasts.31 Electron microscopy of fibroblasts
from AIF Arg201Δ patients showed typical features of parthanatos, with high
chromatinolysis but without any apoptotic bodies.31 These results suggested that the
chromatinolysis activity of AIF is higher in the AIF Arg201Δ mutant relative to wild-type
AIF. Treatment with riboflavin, an FAD precursor, partially improved mitochondrial
complex I activities and staurosporine-induced cell death in AIF mutant fibroblasts.31 In
addition, prolonged riboflavin supplementation was reported to ameliorate the clinical status
of an AIF Arg201Δ patient.31 Further studies are needed to test and evaluate the prevalence
of this mutation in other populations and the efficacy of riboflavin supplementation.
Another human disease related to AIF is familial autosomal dominant optic atrophy caused
by mutations in the OPA1 gene which encodes optic atrophy 1 (OPA1), a dynamin GTPase.
Dominant optic atrophy is characterized by blindness due to the loss of retinal ganglion
cells, leading to optic neuropathy.59 Zanna et al showed OPA1 improved activity of
mitochondrial complex enzymes by direct interactions with mitochondrial complex proteins,
including AIF.59 Future studies are required to understand how AIF-OPA1 interactions
influence mitochondrial complex 1 activity.
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Recent evidence suggests an important apoptotic role for AIF in intestinal epithelial cells
exposed to pathogenic bacteria. Infecting adenocarcinoma cells with Helicobacter pylori or
human epithelial cells with Acinetobacter baumannii and Pseudomonas aeruginosa induces
apoptosis and has been shown to involve AIF.60–63 AIF has also been implicated in
intestinal epithelial apoptotic cell death upon exposure of cells to Citrobacter rodentium and
enteropathogenic Escherichia coli.63,64 Knockdown of AIF in HeLa cells by siRNA blocked
apoptosis induced by enteropathogenic E. coli, providing further evidence for an important
apoptotic role of AIF in bacterial infections in the gut.63
Therapeutic outlook
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Studies investigating the therapeutic potential of AIF have pursued strategies for either
blocking or increasing AIF apoptotic activity. One approach for interfering with AIF
apoptosis involves HSP70. As noted above, HSP70 is a cytosolic binding partner of AIF and
acts to sequester AIF in the cytosol, blocking the apoptotic activity of AIF. Apoptosis and
gastric lesions in the small intestine induced by the nonsteroidal anti-inflammatory drug,
indomethacin, were significantly decreased in transgenic mice overexpressing HSP70.65
These transgenic mice were also protected against neonatal hypoxicischemic brain injury
due to increased sequestering of AIF in the cytosol and therefore lower AIF-dependent
apoptosis.66 Mice lacking HSP70 show increased apoptosis in the heart after ischemiareperfusion, providing additional evidence for the regulation of AIF apoptosis by HSP70.67
An HSP70 gene polymorphism has been shown to be associated with schizophrenia,68 but
whether the underlying mechanisms involved alter AIF apoptotic activity remains unknown.
Studies of AIF binding to the HSP70 mutant would provide important insights into this
question.
Strategies that prevent AIF release from the mitochondria have also been pursued. Calpain
inhibitors, such as MDL28170, PDI150606, AK275, and AKT295, have been shown to
block AIF release in rat models of ischemia, Parkinson’s disease, and retinitis pigmentosa,
suggesting a new therapeutic approach.27 INO1-1001, a PARP-1 inhibitor, improves the
function of the perfused heart in diabetic rat models. Inhibition of PARP-1 is predicted to
decrease AIF release from the mitochondria and apoptosis. Thus, drugs that target PARP-1
block AIF apoptosis which would be a potential therapeutic benefit in the treatment of
myocardial ischemia.27,69
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Approaches to activate AIF apoptotic function have been of primary interest in cancer
research. Overexpression of AIF in gastric cancer, hepatocellular carcinoma cells, and
osteosarcoma cells resulted in increased drug-induced apoptosis.70 Thus, various therapeutic
methods to increase AIF apoptotic activity have been explored. Drugs that target AIF release
and apoptosis induction in cancer have recently been reviewed.27 Here, we will discuss just
a few of the approaches.
One study sought to diminish the sequestering of AIF in the cytosol by disrupting HSP70AIF interactions. In a colon cancer model, rats injected with the synthetic AIF peptide (150–
228 residues) exhibited an improved response with cisplatin-induced apoptosis.55,71 Similar
results were obtained in mouse melanoma cells treated with the AIF peptide, with no
harmful effect on the normal cell population.70,71 These results show that targeting HSPAIF interactions may be a promising method for sensitizing cancer cells to chemotherapy.
Atiprimod (also known as azaspirane), a drug studied for treatment of multiple myeloma,
was shown to trigger apoptosis in mantle cell lymphoma by a caspase-independent pathway
involving AIF.72,73 Atriprimod activates c-Jun N-terminal kinase and upregulates Bax, Bak,
and phosphorylated Bcl2, resulting in elevated AIF release from the mitochondria.73
Sulindac, a nonsteroidal anti-inflammatory drug widely used to treat colon cancer, has also
been shown to act mainly by activating AIF-mediated cell death in colon cancer cells (HT29
cells) which have dysfunctional p53.70,74
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Although there has been significant progress in our understanding of AIF in the short time
since its discovery, significant gaps remain in our knowledge of AIF. Future studies need to
explore physiological redox partners for AIF, determine the mechanisms by which AIF
enhances complex I activity, and identify other accessory proteins involved in the
translocation and apoptotic function of AIF. Tackling these challenging studies may lead to
improved treatment of neurodegenerative diseases and cancer.

Proline dehydrogenase
Human proline dehydrogenase, also known as proline oxidase, is an inner mitochondrial
membrane flavoenzyme encoded by the PRODH1 gene located on chromosome 22q11.2.
Proline dehydrogenase catalyzes the first step in proline catabolism by oxidizing proline to
Δ1-pyrroline 5-carboxylate (P5C) which is then hydrolyzed nonenzymatically to γglutamate semialdehyde.75,76 γ-Glutamate semialdehyde is next converted to glutamate in
an NAD+-dependent step by the enzyme P5C dehydrogenase.75,77 P5C dehydrogenase is
also localized in the mitochondria, thus, the conversion of proline to glutamate occurs
exclusively in the mitochondrion.78
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A kinetic study of purified human proline dehydrogenase has not yet been performed, but
significant insights have been gained from the related proline utilization A (PutA) enzyme in
Gram-negative bacteria and proline dehydrogenase from Thermus thermophilus
(TtPRODH).79 PutA is a bifunctional enzyme which combines proline dehydrogenase and
P5C dehydrogenase domains in the same polypeptide.79 The proline dehydrogenase domain
in PutA from E. coli and TtPRODH share high sequence conservation in the active site with
human proline dehydrogenase, thus providing important insights into the mechanism and
structure of human proline dehydrogenase.80 The proline dehydrogenase domain of PutA
(PutA/PRODH) and TtPRODH is a (βα)8 barrel core structure that noncovalently binds the
FAD cofactor.79 The (βα)8 barrel core is predicted to be similar to the catalytic core of
human proline dehydrogenase.81 Residues that are critical for proline binding in E. coli
PutA, such as Arg555 and Arg556, are conserved in human proline dehydrogenase (Arg479
and Arg480).81 The proline dehydrogenase reaction can be separated into reductive and
oxidative half-reactions. In the reductive half-reaction, proline dehydrogenase catalyzes the
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two- electron oxidation of proline, forming FADH2 and P5C.82 The reductive half-reaction
has been proposed to occur by a hydride transfer mechanism from proline to the FAD bound
in E. coli PutA/proline dehydrogenase.83 In the oxidative half-reaction, PutA/proline
dehydrogenase catalyzes the electron transfer from reduced FAD to membrane-bound
ubiquinone.82 The kinetic mechanism of the proline:ubiquinone oxidoreductase reaction was
recently shown to occur for PutA/proline dehydrogenase via a ping-pong mechanism with
proline and ubiquinone binding at two distinct sites.82 Human proline dehydrogenase may
use a similar mechanism for transferring reducing equivalents from FADH2 to ubiquinone in
the mitochondrial electron transport chain.77
Apoptosis and signaling

PRODH1 is a p53-inducible gene (PIG6) that has a crucial role in apoptosis.84 The
mechanisms involving proline dehydrogenase and induction of apoptosis are illustrated in
Figure 2. Overexpression or upregulation of proline dehydrogenase leads to increased
proline oxidation in the mitochondria and superoxide production.85 In colon cancer cells
expressing wild-type p53, proline dehydrogenase expression was induced by adriamycin,
whereas in cells that lacked a functional p53, proline dehydrogenase expression was
unresponsive to adriamycin.86–90 Thus, cytotoxic drugs such as adriamycin that cause DNA
damage and apoptosis induce proline dehydrogenase expression via p53.
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The mechanism by which proline dehydrogenase contributes to apoptosis has been carefully
studied by Phang et al.75,77,85,87,91–95 Upregulation of proline dehydrogenase expression by
p53 results in increased reactive oxygen species levels which initiate the intrinsic and
extrinsic apoptotic cell death pathways.92 Intrinsic apoptosis is generally characterized by
elevated levels of mitochondrial reactive oxygen species resulting in mitochondrial
membrane damage, cytochrome c and AIF release, and activation of caspase 9.90 Consistent
with intrinsic apoptosis, increased proline dehydrogenase expression causes cytochrome c
release and caspase 9 activation.95 Addition of proline to proline dehydrogenaseoverexpressing cell lines further augments reactive oxygen species-mediated cytochrome c
release and caspase 9 activation.95 Proline dehydrogenase-induced apoptosis is inhibited in
cells overexpressing manganese superoxide dismutase, consistent with an important role for
reactive oxygen species in proline dehydrogenase-mediated apoptosis.96 In addition, P5C
generated by proline dehydrogenase has been shown to promote apoptosis in bladder
carcinoma cell lines and inhibit cell proliferation.86 Thus, the contribution of proline
dehydrogenase to apoptosis may be two-fold, involving reactive oxygen species and the
intrinsic apoptotic pathway, as well as P5C. Whether proline dehydrogenase overexpression
causes release of AIF has yet to be determined.
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In addition to the mitochondrial apoptotic pathway, evidence has been shown for proline
dehydrogenase inducing the extrinsic cell death pathway. Liu et al showed proline
dehydrogenase upregulates TRAIL and DR5 at the mRNA and protein levels.92 Also,
inhibition of caspase 8 resulted in decreased apoptosis by proline dehydrogenase
overexpression.92 The mechanism of TRAIL upregulation by proline dehydrogenase was
shown to be mediated by nuclear factor activated T cells (NFAT).92 Increased cellular
calcium levels are sensed by calmodulin, leading to activation of calcineurin, a Ser/Thr
phosphatase known to activate NFAT by dephosphorylation. Activated NFAT then
translocates from the cytosol to the nucleus to induce TRAIL expression and apoptosis.92
Increased reactive oxygen species are well known to affect intracellular calcium
homeostasis. Proline dehydrogenase-generated reactive oxygen species were also suggested
to mediate the Ca2+/calcineurin-NFAT cascade to activate apoptotic pathways.92
Peroxisome proliferator-activated receptor γ (PPARγ) ligand has been shown to induce the
extrinsic apoptotic pathway in a variety of cancer cells.97,98 The mechanism by which the
PPARγ ligand, troglitazone, induces apoptosis in colon cancer cell lines involves the
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upregulation of proline dehydrogenase and increased generation of reactive oxygen
species.75,87 Triglitazone-induced proline dehydrogenase expression was absent in HCT
cells lacking functional p53 and PPARγ, further indicating a role for PPARγ and p53 in the
regulation of proline dehydrogenase expression.87
Proline dehydrogenase and stress
Proline oxidation plays an important role in cellular redox control that impacts cell survival
and cancer cell growth.75 Earlier work by Phang et al showed that the enzyme actions of
proline dehydrogenase and the cytosolic NADP+-dependent P5C reductase (P5CR) form a
proline-P5C cycle that effectively shuttles reducing equivalents from the cytosol into the
mitochondria.75,77 The proline-P5C cycle helps drive the pentose phosphate pathway by
replenishing NADP+ levels during nutrient stress.87 Although the proline-P5C cycle seems
to have a critical role in cellular redox homeostasis, it is not known yet whether
mitochondria have a specific transporter for P5C in mammals.99
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Proline has also been shown to serve as a microenvironmental stress substrate via proline
dehydrogenase to generate ATP for cell survival under poor nutrient conditions (ie, low
glucose).77,88 Proline dehydrogenase is also induced by AMP-activated protein kinase
(AMPK), a central metabolic sensor kinase and an upstream inhibitor of the mammalian
target of rapamycin complex 1 activity.85,88,100 During nutrient stress conditions, decreased
cellular ATP levels and increased AMP levels act as an allosteric activator of AMPK by
binding to one of the subunits of AMPK.88,101 Recently, it was shown that glucose
deprivation results in increased activity of matrix metalloproteinases 2 and 9, leading to
increased intracellular proline levels, higher proline dehydrogenase expression, and
increased flux of the pentose phosphate pathway.88 This study also suggested that the
proline oxidation pathway generates glutamate and α-ketoglutarate, which can have an
anaplerotic role in the tricarboxylic acid cycle.88
We have previously shown that proline supplementation protects mammalian cells against
various oxidative stress agents and carcinogen-induced apoptosis.102 In addition, overexpression of proline dehydrogenase decreases intracellular proline levels and cell survival
upon exposure to oxidative stress induced by hydrogen peroxide.102 The mechanism by
which proline protects against oxidative stress is unclear, but our unpublished data indicate
that proline dehydrogenase is essential, consistent with the proline-P5C cycle having a
significant impact on the intracellular redox state in mammalian cells. Thus, proline
dehydrogenase expression levels appear to be pivotal in determining whether proline
oxidation has a cell survival role or initiates apoptotic programmed cell death.

NIH-PA Author Manuscript

Therapeutic outlook
Targeting proline metabolism for potential therapeutic applications seems promising in
cancers, schizophrenia, and certain gastrointestinal infections. Proline dehydrogenase
expression is downregulated in many cancer tissues such as renal, colon, rectum, stomach,
liver, and pancreas.93 Thus, proline dehydrogenase has been suggested to be a novel
mitochondrial tumor suppressor and a potential target for cancer therapy. Recently, ectopic
overexpression of miR-23b* in renal cancer cell lines was shown to decrease proline
dehydrogenase expression.103 In miR23b* knockout cells, proline dehydrogenase expression
was elevated relative to control cells. It was also confirmed that miR23b* binds to the 3′untranslated region of proline dehydrogenase mRNA.103 Thus, it was suggested that
inhibiting miR23b* could be a potential strategy for upregulating proline dehydrogenase in
renal cancer cells.103 Additional studies addressing the upregulation of proline
dehydrogenase as a potential cancer therapy are needed.
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Inborn errors of proline dehydrogenase are manifested in type I hyperprolinemia and
neurological disorders such as schizophrenia and increased incidence of seizures.104 The
PRODH1 gene on chromosome 22q11 is located near the centromeric end of the region
which is deleted in Velocardiofacial syndrome/DiGeorge syndrome. Jacquet et al identified
a complete deletion of the PRODH1 gene locus in a subset of schizophrenic patients with
hyperprolinemia.105,106 Another study showed microdeletion of PRODH1 is strongly
associated with schizophrenia and 22q11 DiGeorge syndrome.107 Missense mutations in the
PRODH1 gene found in patients with type I hyperprolinemia were characterized and shown
to result in mild to severe reduction in proline dehydrogenase activity. Mutations associated
with schizophrenia were found to have a severe reduction in proline dehydrogenase activity
indicating that dysfunctional proline dehydrogenase may be a risk factor in
schizophrenia.108 The mechanism by which aberrant proline dehydrogenase and proline
metabolism possibly contributes to mental disorders is not known. Novel therapeutics aimed
at maintaining normal proline levels in the central nervous system may be a worthwhile
strategy for treating certain cases of schizophrenia.
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Proline levels in the gastric juice of patients infected with H. pylori were reported to be 10fold higher than in control subjects.109,110 Proline has been shown to be a preferred
respiratory substrate of H. pylori in the gut.109 We and others have shown that knocking out
the putA gene in Helicobacter significantly reduces infection rates and inflammation of the
liver in mice relative to wild-type Helicobacter strains, indicating that PutA and proline
metabolism is important for virulence.110,111 Thus, inhibiting PutA/proline dehydrogenase
with small molecules such as tetrahydro-2-furoic acid, a competitive inhibitor of proline
dehydrogenase, may be beneficial for treating infections of H. pylori, the causative agent of
peptic ulcers.

NADPH oxidase
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NADPH oxidase enzymes share a catalytic core comprising a FAD cofactor, two heme
cofactors, and a transmembrane domain anchor.112 In the reaction catalyzed by NADPH
oxidase, a hydride is transferred from NADPH to FAD followed by single electron transfer
steps from the reduced FAD to the hemes, where molecular oxygen is reduced to
superoxide. The overall electron transfer pathway involving NADPH (Em = −320 mV), FAD
(Eox/sq = −256 mV, Esq/red = −304 mV),113 heme (Em = −245 mV),114 and the dioxygen/
superoxide couple (Em = −160 mV) isthermodynamically favored. The transmembrane
domain orients NADPH oxidase to enable electron flow across the membrane, with NADPH
oxidation occurring on one side of the membrane and reduction of dioxygen occurring on
the opposite side. Thus, electrons are effectively shuttled from cytosolic NADPH to
molecular oxygen in intracellular or extracellular compartments. The physiological function
of NADPH oxidase was originally considered only to be the phagocyte respiratory burst to
kill invading microorganisms. With the discovery of several NADPH oxidase isoforms,
additional cellular functions beyond host defense have now emerged.
NADPH oxidase subunits and regulation
The NADPH oxidase family of enzymes is comprised of seven isoforms (NADPH oxidase
1–5 and Duox1 and 2) which all share a redox catalytic core and a transmembrane binding
domain. Previous reviews have provided excellent summaries of the structural features and
regulation of the different NADPH oxidase isoforms.112,115–117 Here we will only provide a
brief summary.
Nox2 (also known as gp91phox) is the isoform of NADPH oxidase expressed in white blood
cells and is responsible for the respiratory burst associated with the phagocytic killing of
microbes. Nox2 forms a heterodimer with p22phox, a membrane-associated subunit, to form
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a complex known as flavocytochrome b558.118 Regulatory subunits involved in activating
Nox2/p22phox are p47phox, p67phox, p40phox, and Rac1/Rac2.118,119 Upon cell activation,
these regulatory subunits assemble with Nox2/p22phox to form an active NADPH oxidase
complex. The formation of an active Nox2 complex is GTP-dependent via Rac1/Rac2 and is
upregulated by phosphorylation of cytosolic factors, p47phox and p40phox.116
Phosphorylated p47phox then binds the p67phox subunit to provide a binding site for GTPRac which then results in activation of Nox2 enzyme.112,120–122
Nox1 forms a heterodimer with p22phox and is activated by regulatory subunits Noxo1
(NADPH oxidase organizer 1, analogous to p47phox), Noxa1 (NADPH oxidase activator 1,
homolog of p67phox), and GTP-Rac1.116 Nox1 and Nox2 function in host defense by
protecting against invasive pathogenic bacteria in the colonocytes.123 Nox3 activity relies on
p22phox and is primarily regulated by Noxa1. Nox4 also requires p22phox but appears to be
active without any regulatory subunits. Thus, it has been suggested that Nox4/p22phox is
constitutively active. Nox4 has been confirmed to have a role in mitochondrial dysfunction
and cardiac damage during pressure overload.124 Recently, a role for Nox4 in DNA damage
induced by conditional overexpression of oncogenic H-Ras in primary human thyrocytes
was reported.125
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Nox5 is distinguished by four EF-hand motifs in the N-terminus on the intracellular side of
the membrane that allow regulation of NADPH oxidase activity by calcium. Duox 1 and 2
have two EF-hand motifs and an N-terminal extracellular peroxidase homology domain.
Similar to Nox5, the EF-hand motifs of Duox 1 and 2 are on the intracellular membrane
side, allowing for activation by calcium binding.112,116,126 The function of the peroxidase
domain is not fully known because residues important for peroxidase activity are lacking.
However, the peroxidase domain has been proposed to have superoxide dismutase activity
which would facilitate the conversion of superoxide into hydrogen peroxide, the substrate
for thyroperoxidase, which is essential for hormone synthesis.127
Apoptosis and signaling
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NADPH oxidase isoforms have been shown to have beneficial and detrimental effects,
depending on the type and amount of reactive oxygen species generated. NADPH oxidase
enzymes can differentially modulate the intracellular redox state and impact cell signaling
pathways that promote cell survival or apoptosis. Regulated reactive oxygen species
generation is necessary for redox signaling, while prolonged reactive oxygen species
generation favors apoptotic pathways.117 Figure 3 highlights how reactive oxygen species
generated by the activation of NADPH oxidase lead to apoptosis. Several studies using
different mammalian cell types have shown that NADPH oxidase activity inactivates protein
tyrosine phosphatase.116,117,126 Downregulation of protein tyrosine phosphatase results in
activation of the receptor tyrosine kinase and downstream pathways, such as extracellular
signal-regulated kinase/mitogen activated protein kinase, c-Jun N-terminal kinase, and
phosphatidylinositol 3-kinase/Akt (a serine/threonine protein kinase), which regulate cell
survival and apoptosis in response to stress.116 Thus, NADPH oxidase-generated reactive
oxygen species, presumably H2O2, can serve as a signaling molecule that mediates cell
adaptation to stress and life/death outcomes.
NADPH oxidase-generated reactive oxygen species have also been shown to stimulate the
secretion of cyclophilin A (a main player in AIF-DNA binding complex) resulting in
activation of extracellular signal-regulated kinase/mitogen activated protein kinase.128
NADPH oxidase-generated reactive oxygen species also upregulate AIF gene expression
during cerulein-induced apoptosis in rat pancreatic acinar cells.129 Nox1 has been shown to
facilitate formation of the TNFα-TNF receptor type 1 complex which includes associated
death domain protein, receptor interacting protein, and Rac, resulting in c-Jun N-terminal
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kinase-mediated apoptosis.112,130 Nox4 has also been shown to be involved in TNF-α
mediated apoptosis in cerebral vascular endothelial cells.131 Nox2 in macrophages and Nox4
in astrocytes result in reactive oxygen species which activates apoptosis by activating the
apoptosis signal-regulating kinase 1-p38 mitogen activated protein kinas/c-Jun N-terminal
kinase pathway leading to apoptosis.117,132 Recently, DR4 and DR5 have been shown to
activate Nox1 directly, independent of death-inducing signaling complex-mediated
apoptosis. Here, NADPH oxidase-generated superoxide was responsible for the sustained
activation of c-Jun N-terminal kinase-dependent apoptosis.133,134
NADPH oxidase and disease
Involvement of NADPH oxidase in the pathogenesis of several diseases is well established.
The most familiar case is Nox2 (gp91phox) deficiency, which causes chronic granulomatous
disease, a primary immunodef iciency affecting phagocytosis of the innate immune
system.135,136 Patients with chronic granulomatous disease are more susceptible to certain
types of bacterial and fungal infections due to dysfunctional phagocytes that lack proper
NADPH-dependent superoxide formation.136 Mice def icient in Nox2 develop symptoms of
granulomatous disease as well, but also display a second phenotype of balance order
dysfunction and defective otoconia formation.135 This suggests that Nox2 is involved in
otoconium formation, a structure in the utricle of the inner ear, which helps in sensing
gravity and linear acceleration.135
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Evidence for NADPH oxidase-derived reactive oxygen species contributing to the
progression of cardiovascular disease,137 pulmonary diseases, lung cancer,138 human
atherosclerosis,139 myocardial angiogenesis in ischemic heart disease,140 and angiotensin IIinitiated apoptosis of neonatal cardiomyocytes141 have been reported. In humans,
atherosclerosis is associated with increased Nox1 and Nox2 expression.142 Atherogenic
particles such as oxidized low-density lipoprotein have been shown to induce NADPH
oxidase-dependent endothelial cell activation and injury which is the underlying cause of
atherosclerotic plaque formation.143,144 Similar to oxidized low-density lipoprotein,
advanced glycation end products can induce NADPH oxidase activity, leading to increased
reactive oxygen species and induction of apoptosis in a caspase 3-dependent manner during
diabetic retinopathy.133,134,145 In addition, the advanced glycation end product precursor, 3deoxyglucosone, induces stress in the endoplasmic reticulum and apoptosis in dermal
fibroblasts through activation of Nox4.146
Therapeutic outlook
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Recent comprehensive reviews have discussed the inhibition of NADPH oxidase as a
therapeutic target for cardiovascular disease, diabetes, fibrosis, hyperlipidemia, Alzheimer’s
disease, and β-cell dysfunction.116,147–151 Here, we will provide some of the recent
advances and perspectives.
Reactive oxygen species derived from Nox1 were shown to activate murine hepatic stellate
cells.152,153 Activated hepatic stellate cells produce extracellular matrix proteins which lead
to liver fibrosis.154 Recently, it was shown that Nox1 knockout mice are less susceptible to
liver injury and fibrosis.155 The mechanism of liver injury and fibrosis associated with Nox1
was proposed to involve reactive oxygen species inactivation of phosphatase and tensin
homolog (PTEN). Inactivation of PTEN leads to enhanced signaling of pathways involving
the Akt/Fork head family of transcription factor Class O (Foxo4) to induce cell
proliferation.155 NADPH oxidase enzyme activity has also been reported to lead to
activation of pancreatic stellate cells and subsequent pancreatic fibrosis and inflammation in
mice.156 Thus, targeting Nox1 may have therapeutic benefits for treatment of chronic liver
and pancreatic fibrosis.
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In contrast with apoptosis, Nox4 appears to have an important role in cancer cell growth and
survival which can influence disease progression. Upregulation of Nox4 activity by
overexpression of Akt in melanoma cells leads to increased cancer metastasis.157 Reactive
oxygen species generated by Nox4 inhibits apoptosis of pancreatic cancer cells.158
Downregulation of Nox4 by AMPK was shown in a mouse model of type I diabetes,
suggesting that low Nox4 activity may be a contributing factor in diabetes.159 The
prosurvival role of NADPH oxidase has also been documented in prostate cancer cells160
and ovarian cancer cells.161 Thus, inhibition of the specific NADPH oxidase isoform would
be a potential therapeutic strategy for the treatment of cancer.
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Inhibition of NADPH oxidase in animal models was demonstrated with diphenyl iodonium,
an inhibitor that disrupts the physiological oxidative half-reaction by acting as an alternative
electron acceptor for reduced FAD. However, diphenyl iodonium is a nonspecific inhibitor
of NADPH oxidase because it also inhibits several other flavoproteins, including
mitochondrial complexes I and III, cytochrome P450 oxidoreductase, xanthine oxidase, and
nitric oxide synthase.147,162,163 Another inhibitor of NADPH oxidase is the natural organic
compound, apocynin, which can decrease superoxide production by Nox2 in phagocytes.
Apocynin inhibits the assembly of activated Nox2 by interfering with interactions between
the Nox2/p22phox heterodimer and the regulatory subunits, p47phox and p67phox.164
However, using apocynin as an NADPH oxidase inhibitor in nonphagocyte cell types is
somewhat controversial. Apocynin has been reported to function as an antioxidant in
vascular smooth muscle cells by forming an apocynin radical which then scavenges reactive
oxygen species.165 In contrast, another group reported that apocynin helps generate reactive
oxygen species in nonphagocytic cell types.166
One strategy that was pursued for specific inhibition of Nox1 and 2 was targeting p22phox
interactions with the regulatory subunit p47phox which is essential for the activation of Nox1
and Nox2.118,121,167 Targeting the activation of Nox1 and 2 may be therapeutically useful
for the diseases in which Nox1 and 2 activation have pathological consequences. Thus,
synthetic peptides designed to interfere with p22phox–p47phox interactions have been tested.
Synthetic peptides containing the p47phox interacting domain of Nox2 conjugated to the HIV
transactivator transcription protein were shown to decrease reactive oxygen species
generation significantly in vascular smooth muscle cells and attenuate systolic blood
pressure in a mouse model of hypertension.168 Although peptide inhibitors of NADPH
oxidase show promising effects in animal models, oral bioavailability and immune response
over long-term use remains an open question.
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New potent compounds developed by pharmaceutical companies such as pyrazolopyridines
(GKT-136901 and GKT137891)169 and triazolopyrimidines (VAS2870 and VAS3947) have
been reported to inhibit NADPH oxidase, with IC50 values below the μM range, and are
bioavailable through oral administration.147,169 These compounds are proposed to be
competitive inhibitors of NADPH oxidase with respect to NADPH. However, the above
compounds appear to lack NADPH oxidase isoform specificity.151 Further studies are
required to elucidate the clinical efficacy and safety of these NADPH oxidase inhibitors.

Conclusion
The three flavoproteins discussed here are involved in different pathways of apoptosis.
Various approaches for manipulating AIF, proline dehydrogenase, and NADPH oxidase
activity have been pursued in efforts to enhance or diminish apoptosis in the context of
different diseases. Strategies for developing therapeutics involving AIF, proline
dehydrogenase, and NADPH oxidase need to consider the multifaceted and complex roles of
these enzymes in different cell types. Upregulation of AIF and proline dehydrogenase
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apoptotic mechanisms may be useful for developing novel adjuvant therapies in cancer
treatment. Interestingly, blocking human AIF in combination with small molecule inhibitors
of PutA/proline dehydrogenase may also be of therapeutic use in fighting intestinal
pathogenic bacterial colonization/infections. The wide ranging physiological roles of
NADPH oxidase provide unique opportunities for targeting specific NADPH oxidase
isoforms in the treatment of several diseases, in particular cardiovascular disease, diabetes,
and Alzheimer’s disease.
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Figure 1.
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AIF and intrinsic pathway of apoptosis. Stress stimuli, such as oxidative stress, induce
cleavage of mAIF in the mitochondria to tAIF by calpain. Newly formed tAIF escapes from
the mitochondria and interacts with cyclophilin A in the cytosol to facilitate translocation
into the nucleus. Alternatively, the chaperone, HSP70, can bind tAIF, resulting in
sequestration of tAIF in the cytosol and inhibition of AIF-dependent apoptosis. In the
nucleus, tAIF forms a DNA degrading complex with phosphorylated histone, γH2A.X, and
cyclophilin A to induce DNA fragmentation and apoptosis. AIF release from the
mitochondria is also increased by the action of poly (ADP-ribose) polymerase 1 (PARP-1)
and PAR polymers.
Note: *Indicates potential target in the AIF pathway for therapeutic intervention.
Abbreviations: AIF, apoptosis-inducing factor; tAIF, truncated apoptosis-inducing factor;
HSP, heat shock protein; mAIF, mature apoptosis-inducing factor.
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Figure 2.

Proline dehydrogenase and classical apoptotic pathway. DNA damage induces both the
extrinsic and intrinsic pathway of apoptosis by increasing the expression of death receptors
and p53, respectively. Proline dehydrogenase in the mitochondria is upregulated by p53.
Oxidation of proline by proline dehydrogenase leads to production of pyrroline-5carboxylate (P5C) and FADH2. Electrons from FADH2 are then transferred to the electron
transport chain to produce ATP for survival or superoxide (O2−) and oxidative stress in the
mitochondria. Oxidative stress generated by proline dehydrogenase induces the release of
cytochrome c from the mitochondria, resulting in the formation of an apoptosome involving
activated caspase 9, which then activates downstream caspases 3, 6, and 7 to induce
apoptosis. It is not known whether proline dehydrogenase also induces mitochondrial release
of AIF.
Abbreviations: PRODH, proline dehydrogenase; AIF, apoptosis inducing factor; cyt c,
cytochrome c; FAD, flavin adenine dinucleotide; FADD, Fas-associated death domain;
ETC, electron transport chain; BID, BCL-2 interacting domain; tBID, truncated BCL-2
interacting domain.
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Figure 3.
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NADPH oxidase and apoptotic signaling. Protein kinase C/Akt can activate Nox1 and Nox2
by phosphorylation of cytosolic subunits such as p47phox. Activated Nox1 and Nox2
produce superoxide radical (O2−) which dismutates to hydrogen peroxide (H2O2). NADPH
oxidase-generated H2O2 acts as a signaling molecule that affects signaling pathways leading
to apoptosis. H2O2/reactive oxygen species generated by NADPH oxidase inactivates
protein tyrosine phosphatase, which indirectly activates the ERK, MAPK, and c-Jun Nterminal kinase pathways of apoptosis. NADPH oxidase-generated H2O2 can also activate
apoptotic signal-regulating kinases, increase AIF-CypA interactions, and increase protein
and DNA damage resulting in apoptosis.
Abbreviations: Nox, NADPH oxidase; AIF, apoptosis-inducing factor; PTP, protein
tyrosine phosphatase; CypA, cyclophilin A; MAPK, mitogen-activated protein kinase; ERK,
extracellular signal-regulated kinase; ASK, apoptosis signal-regulating kinase; JNK, c-Jun
N-terminal kinase.
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